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Abstract
Background. Evidence-based medicine (EBM) has become widely accepted as a basis for clinical decision in many fields
of medicine. This review examines the specific role of EBM in hepato-biliary and pancreatic (HBP) surgery. EBM relies on
four main sources, including clinical guidelines, meta-analyses, primary information and clinical experience. Randomized
controlled trials (RCTs) constitute the cornerstone of EBM and a recent study reported that there are relatively few RCTs
evaluating the effectiveness of surgical therapies and procedures (1,530 out of 45,342 or 3.4% in five leading surgical
journals) and only a few in HBP surgery. Although the effort must be to implement EBM as far as possible in HBP surgery,
there are several obstacles to conducting RCTs in HBP surgery, including problems associated with standardization of
surgical skills, sham-operations often impossible to perform, and the general applicability of specific findings may be
uncertain.
Discussion. This paper will provide two relevant examples of EBM in HBP surgery in patients with hepatic metastases
and pancreatic adenocarcinoma, illustrating some problems but also the potential of introducing EBM in HBP surgery. In
the future, our effort must be devoted to implementing EBM in applicable areas of HBP surgery but also remembering that
in certain areas accumulated knowledge from observational studies, including drainage of abscesses and surgical treatment
of intestinal obstruction, may have similar or even higher clinical value than RCTs.
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Evidence-based medicine (EBM) implies the need
to base clinical decisions on the results of scientific
investigations. EBM has been increasingly advo-
cated in all specialties during recent years to evaluate
specific therapies and procedures. Surgery is no
exception. The definition of EBM is ‘the use of best
available evidence for devision for the individual
patient’. One of the founders of EBM stated: ‘It’s
about integrating individual clinical expertise and the
best external evidence’ [1]. It is required that in all
instances the quality of the information is given, in
order to make best use of it. It is therefore not enough
to state that scientific evidence exist, but that the
level of scientific evidence is stated. Most modern
textbooks are based on information from experienced
clinicians and researchers. This type of information
is classified as ‘expert evaluation’ and has a low value
(Table I).
The basis for EBM relies on different sources of
information and knowledge:
 clinical guidelines
 reviews/meta-analyses
 primary information
 clinical experience
Clincial guidelines
There are a great number of databases with clinical
guidelines. The quality varies and in many instances
the level of evidence is not stated, which makes it
difficult for the reader to evaluate. Good examples
for clinical guidelines are EBM guidelines (www.ebm-
guidelines.com). EBM guidelines collect, summarize,
and update the core clinical knowledge essential in
general practice. The guidelines also describe the
scientific evidence underlying the given recommen-
dations. EBM guidelines have been produced over 15
years as a joint venture of the Finnish Medical Society
Duodecim, a scientific organization of Finnish physi-
cians and Duodecim Medical Publications Ltd.
The methods to guarantee the quality of guidelines
include: (1) continuous peer review process of up-
dating by editors, authors and referees; and (2) linking
to the best evidence. The editors evaluate all Cochrane
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and DARE systematic reviews and cooperate with
other international guidelines.
There are more than 1000 guidelines, but a limited
number within the field of HBP-surgery.
Reviews/meta-analyses
The reviews are based on analyses of primary scientific
studies. The most important is the Cochrane Library
(www.update-softwhere.com/cochrane/default.htm).
The Cochrane Collaboration is an international non-
profit and independent organization, dedicated to
making up-to-date and accurate information about
the effects of healthcare readily available worldwide.
It produces and disseminates systematic reviews of
healthcare interventions and promotes the search for
evidence in the form of clinical trials and other studies
of interventions. The Cochrane Collaboration was
founded in 1993 and named for the British epidemi-
ologist, Archie Cochrane. Also in these cases few
reviews are given within the field of HBP-surgery.
Primary information
The most important source of information is in
MEDLINE.
Clinical experience
This relies on the experience accumulated from obser-
vational studies and is the type of knowledge that is
of importance for surgical patients.
When reviewing ‘evidence-based surgery’, it be-
comes apparent that much less EBM information
is available on HBP-surgery than for many other
specialties. A recent analysis of the MEDLINE data-
base (1996–2000) confirms this. Of the 134,689
published randomized controlled trials, only 20,376
(15.1%) dealt with surgical contents [2]. In a detailed
analysis out of all articles (45,342) in five leading
journals (Annals of Surgery, Archives of Surgery,
British Journal of Surgery, World Journal of Surgery),
only 3.4% (1,530) of all papers were randomized
controlled trials. In a further analysis many did not
fulfil the criteria for good standards or were mislabeled
and had to be excluded. In addition 55% of all RCTs
in the analyzed surgical journals dealt with medical
therapies in surgical patients. Thus, only 287 articles
compared different surgical procedures or operations
to conservative treatments.
There are several reasons for this lack of RCTs
in surgery. One important reason is the reliance
on RCTs as the cornerstone of EBM. The value
of RCT is however limited in surgery. There are
four main reasons limiting the value of RCTs in
surgery [3].
1. Experimentation may be unnecessary
When an effect of an intervention is dramatic (e.g. liver
transplantation for end-stage liver disease), the like-
lihood of unknown factors being important is very
small.
2. Experimentation may be inappropriate
This is the case when RCTs are not large enough
to quantify accurately infrequent adverse outcomes.
Another example is when the outcome of a specific
procedure can be determined only far in the future, e.g.
evaluation of artificial joints. Furthermore, sometimes
it remains difficult to standardize the tested surgical
procedures because they will evolve continuously and
because the complications decrease as surgeons over-
come the learning curve and gain increasing experience
with a new procedure. In addition, the skills of the
individual surgeon vary and therefore all surgeons
participating in a RCT should undergo appropriate
training to achieve optimal standardization [4].
3. Experimentation may be impossible
The surgeon may be reluctant to participate in a trial
because of clinical uncertainty. There may also be
ethical considerations to randomize patients to an
operation or medical therapy. Finally it may be im-
possible to perform a proper sham operation, although
we know that sham operations may play a role [5].
4. Experimentation may be inadequate
The general applicability of the results of RCTs is often
low [6]. The outcome of surgery may be highly
Table I. Level of evidence
Code Level Definition
A Strong research-based evidence Several relevant high-quality scientific studies with homogenous
results – randomized controlled studies.
B Moderate research-based evidence At least one relevant, high-quality study or several adequate
studies. Cohort studies. Case-control studies.
C Limited research-based evidence At least one adequate scientific study – consensus statements,
case studies, descriptive studies.
D No scientific evidence Expert panel evaluation or other information.
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dependent on the characteristics of the provider, the
setting, and the patients.
EBM in HBP-surgery
A summary of the available EBM in HBP-surgery is
shown in Table II. In line with findings described
above, only a few guidelines and evidence deal with
surgical interventions.
The reasons for this lack of EBM may be sought
from the description mentioned above. Here we will
give two examples of the problems involved in HBP-
surgery: (1) Much controversy surrounds the value of
surgical treatment of malignancies; (2) there are no
RCTs comparing surgical resection of hepatic metas-
tases to no therapy or medical therapy.
The closest we have come to a controlled study is a
report from the Mayo Clinic in 1983 [7]. In this study
of patients with liver metastases of colorectal origin
referred for evaluation, all patients underwent the same
work-up before acceptance to resection. Out of a group
of patients fulfilling the criteria for resection, some
were only biopsied and not operated and in this group
all patients were dead within 7 years, whereas 30%
of resected patients were alive at the same time
(Figure 1).
This was not a randomized trial, but gives a strong
indication of the value of hepatic resections in this
category of patients. These results are from one center
with a vast experience in liver resections, but the results
may not be generalizable. However, the long-time
survival of 30% in patients undergoing liver resection
in this study is in line with results from several other
large and multi-institutional series (including 5,765
patients) [8]. This has led to the conclusion that liver
resection provides a clear survival advantage in patients
with hepatic metastases. The level of evidence is C,
which in our opinion is considered too low. It is known
that there may be spontaneous regression of tumor
growth in the liver, but that is extremely rare and
should therefore not be accounted for in comparison to
results of therapy [9].
Today we know, from several studies on prognostic
factors, which patients actually benefit from surgery
and therefore liver resections remains the standard
therapy in patients with a limited number of tumor
deposits in the liver and no extrahepatic spread. The
results may be improved even further with adjuvant
cytotoxic therapy as is the case in other gastrointestinal
malignancies.
When it comes to another common malignancy—
pancreatic adenocarcinoma—the situation is more
difficult. In spite of the progress in surgical treatment,
resulting in increasing radical resection rates and a
decrease in treatment-related morbidity and mortality,
less than 3% of patients with pancreatic adenocarci-
noma are cured today [10].
Major contributions to improved surgical treatment
results include the reduction of hospital mortality and
treatment in high-volume centers.
Do we have evidence that surgical treatment is
justified? No randomized study has been performed
comparing surgery in resectable patients to best
supportive care or medical therapy. Such a study
would be difficult to perform, because although
surgery offers a low curative rate, it is the only chance
for survival.
Table II. EBM in HBP-conditions, modified from reference [8]
Condition
Level of
evidence
Mortality and complications of
laparoscopic cholecystectomy
B
Bile acid therapy for gallstone dissolution A
Sphincterectomy for biliary sphincter
of Oddi dysfunction
C
Treatment of hepatocellular carcinoma D
Hepatic resection as a treatment for liver
metastases in colorectal cancer
C
Regional versus systemic chemotherapy
for colorectal cancer metastatic to the liver
A
Portal vein chemotherapy in colorectal cancer C
Emergency sclerotherapy versus medical
interventions for bleeding oesophageal
varices in cirrhotic patients
B
Somatostatin or octreotide for acutely
bleeding oesophageal varices
B
Somatostatin, octreotide and gabexate
mesilate for acute pancreatitis
B
Prophylactic antibiotics for severe acute pancreatitis B
Predicting gallstone pancreatitis with laboratory
parameters
C
Enteral versus total parenteral nutrition
for acute pancreatitis
C
Chemotherapy in advanced pancreatic
adenocarcinoma
C
Pancreatic enzyme supplementation in the
treatment of pain in chronic pancreatitis
D
Figure 1. Survival in patients with liver metastases from colorectal
cancer undergoing operation or no therapy. From: Adson and
Van Heerden [7].
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Several case-control studies have shown that surgical
resection as well as chemotherapy can prolong survival
in pancreatic cancer. The number of patients who
benefit from treatment is, however, still limited. The
assessment of clinical benefit from surgical or medical
cancer treatment should be based on several endpoints
beyond actuarial survival data. Progression-free sur-
vival may be more appropriate to evaluate surgery.
In the palliative setting, survival prolongation is of
greatest importance.
Increasingly important is to assess quality of life
(QoL) aspects using the European Organization for
Research and Treatment of Cancer (EORTC) supple-
mented with a disease-specific questionnaire module
for patients with pancreatic cancer referred to as
QLQ-(30) [11] or a standard functional assessment
of hepatobiliary cancer treatment LFACT-Hep [12].
Therefore, in pancreatic cancer treatment trials,
reporting results after oncologic resections, the pri-
mary endpoints to evaluate treatment efficacy include
median survival, progression-free survival and QoL
measurements.
Despite the lack of EBM for surgical treatment of
pancreatic carcinoma, we think a continuous effort is
justified under the settings described above and with
the trial of adjuvant therapies.
EBM in HBP-surgery—the future
Although we are lacking proper EBM when it comes
to RCTs for many operations used in the field, we
must continue our efforts to improve the situation.
Since as discussed above it may be impossible to
perform RCTs in most of these instances, we must
present data including other useful parameters such
as progression-free survival and QoL in our series.
Clinical experience can be considered as the
accumulated wisdom from studies, and this type of
knowledge is of great value in surgery. Despite the
lack of RCTs many surgical procedures may have a high
level of evidence, which in many instances is higher
than RCTs, e.g. drainage of abscesses and operative
treatment of intestinal obstruction. One can therefore
add one more level to EBM described above:
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